5-OXYMETHYL-4-ACYL-1,3-DIHYDRO-2H-IMIDAZOL-2-ONES

Abstract: 1,3-Dihydro-2H-imidazol-2-ones having 4-acyl and 5-­ oxymethyl substituents, are useful as cardiotonics, anti­ hypertensives and antithrombotic agents. The compounds are obtained by the reaction of an appropriate alcohol or a silver salt with a substituted 4-bromomethyl-1,3-dihydro-2H-­ imidazol-2-one.

Description: 5-CY.YMETHYL-4-ACYL-1,3-DIHYD,RO-2H-IMIDAZOL-2-GNES The present invention relates to imidazoles having an acyl and an oxymethyl substituent at the 4- and 5-positions. More particularly, it relates to compounds having the following general formula: EMI1.1 aMereLn each R independently is hydrogen, lower alkyl of 1 -4c, lower alka- noyl of 2-4 C, or benzoyl; Rl is lower alkyl of 1-4 C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methyl sulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3,4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl; R2 is hydrogen or lower alkyl of 1-4 C; and R3 is hydrogen, lower alkyl of 1-4C, lower alkanoyl of 2-4C and nitro. Examples of the lower alkyl groups referred to above are methyl, ethyl, propyl, isopropyl and butyl. The lower alkanoyl groups referred to above contain 2 to 4 carbon atoms and can be exemplified by acetyl, propionyl and butyryl. Examples of the halophenyl groups referred to above include fluorophenyl, chiorophenyl and bromophenyl. Where R is hydrogen in the compounds of the present invention, several tautomeric forms of the compounds ar posslble as foilows: EMI2.1 wherein the various groups are as defined earlier. These tautomers are acidic and can react with strong bases to form pharmaceutically acceptable salts of the following formulas: EMI2.2 wherein the various groups are defined as above and M is a pharmaceutically acceptable alkali metal such as sodium or potassium. Throughout this disclosure, the term imidazol-2-one shall be taken to mean any of the tautomers or the tautomer salts as set forth above. As examples of compounds of the present invention are the following: 4-Benzoyl-l, 3-dihydro-5- (ethoxymethyl) -2H-imidazol-2- one. 4-Propionyl-l,3-dihydro-5-(ethoxymethyl)-2H-imidazol2-one. 5- (Propionyloxymethyl) -l,3-dihydro-4- (4-methoxyben- zoyl)-2H-imi azol-2-one. 5-(Butyryloxymethyl)-l,3-dihydro-4-'4-methoxybenzOyl)- 2-imidazol-2-one. 4-(3-Pyridylcarbonyl)-5-(butoxymethyl)-l,3-dihydro2H-imidazol-2-one. l,3-Dihydro-4-(4-methoxybenzoyl)-5-(l-methoxethyl)- 2H-imidazol-2-one. 4-Acetyl-l, 3-dihydro-5-hydroxymethyl-2H-imidazol-2- one. l,3-Dipropionyl-l,3-dihydro-4-(4-methoxybenzoyl)-5- (ethoxymethyl) -2H-imidazol-2-one. l,3-Dibenzoyl-l,3-dihydro-4-(4-methoxybenzoyl)-5- (ethoxymethyl)-2H-imidazol-2-one. l,3-Dihydro-l,3-diethyl-4-(4-methoxybenzoyl)-5-(ethOxy- methyl)-2H-imidazol-2-one. The compounds of the present invention are prepared by the bromination of a 1,3-diacetyl imidazolone such as a compound of the formula: EMI3.1 wherein Z is hydrogen to give the compound wherein Z is Br. The reaction is carried out using N-bromosuccinimide in the presence of a free radical initiator such as benzoyl peroxide in an appropriate solvent such as carbon tetrachloride. The specific diacetyl starting materials are obtained from the corresponding 1,3-unsubstituted imidazolone by acetylation with acetyl chloride or acetic anhydride and the unsubstituted imidazolones used are prepared in Belgian Patent No. 883,856 or they can be prepared by the same general procedures described in the patent. The bromomethyl compounds obtained above can be treated with hydrobromic acid in acetic acid to remove one or both of the N-acetyl groups. To obtain the compounds in which R3 is lower alkyl, the resulting imidazolone is then treated with the appropriate alcohol; to obtain the compounds in which R3 is lower alkanoyl or nitro, the bromomethyl imidazolone is treated, respectively, with the silver salt of an appropriate alkanoic acid or silver nitrate. When R3 is hydrogen, the compounds are obtained by preparing the corresponding benzyl ether and then debenzylating by standard procedures. If the starting material contains N-acyl substitution, such groups can be treated with acid to remove the groups when R3 is lower alkyl or lower alkanoyl or an amine can be used when R3 is nitro. Alternatively, the compounds in which R is hydrogen can be converted to compounds in which R is lower alkanoyl or benzoyl by reaction of the compounds in which R represents hydrogen with an excess of the appropriate acid anhydride or acid chloride. The compounds of the present invention can be used in the treatment of hypertension including primary or essential hypertension, hormonally induced hypertension, renal hypertension and chemically induced hypertension. The compounds of the present invention can also be used as anti-thrombotics. They affect the coagulation of blood by preventing the aggregation of blood platelets, which play a dominant role in thrombotic conditions both in the initial event and at the occlusive stage. Arterial thrombosis, particularly in arteries supplying the heart muscle and brain, is a leading cause of death and disability. In addition, the compounds of the present invention in which R3 is hydrogen, lower alkyl or lower alkanoyl can also be used in the treatment of cardiac failure including congestive heart failure, backward heart failure, forward heart failure, left ventricular heart failure, or right ventricular heart failure or in the treatment of any other condition which requires the strengthening of heart action with a cardiotonic. In many respects, these compounds possess digitalis-like action. Antihypertensive activity for the present compounds was demonstrated using groups of 12 spontaneously hypertensive rats. Blood pressure was measured by a pressure cuff occluder around the base of the tails of the rats. The blood pressure was determined in the animals, test compound was administered orally in a vehicle at a dose of 50 mg/kg and blood pressure was measured again at 1, 2, 3, 4 and 24 hours after administration of the test compound. The difference in blood pressure observed was analyzed to establish if it was statistically significant. The vehicle used in administering the test compound did not have a significant effect on blood pressure when used alone. Cardiotonic activity for the present compounds was demonstrated by the following procedure. A Walton-Brodie strain gage arch was surgically implanted on the heart of anesthetized dogs to measure cardiac contractile force. After the vital signs of the animal were stable for 10 minutes, test compound was administered intravenously starting at a dose of 0.3 mg/kg and continuing with higher doses of 1, 3 and 10 mg/kg if no effect is observed. Active compounds, such as compounds of the present invention, which increase cardiac contractile force measured in this way exert a true positive inotropic effect, or a cardiotonic effect. Antithrombotic activity for the present compounds is demonstrated by the following procedure. When adenosine diphosphate is added to citrated platelet rich human plasma, a typical aggregation of blood platelets occurs. Antithrombotic activity is determined by adding a test compound to the citrated platelet rich human plasma in concentrations of 3, 10, 30 and 100 ug/ml and subsequently adding adenosine diphosphate and observing the extent of inhibition of aggregation of blood platelets. The compounds may be administered in various manners to achieve the desired effect. The compounds may be administered alone or in the form of pharmaceutical preparations to the patient being treated either orally or parenterally, that is, intravenously or intramuscularly. The amount of compound administered will vary with the severity of the hypertension, cardiac failure or blood clotting and the mode of administration. For oral administration the antihypertensively effective amount of compound is from about 0.1 mg/kg (milligrams per kilograms) of patient body weight per day to about 100 mg/kg of patient body weight per day and preferably from about 5 mg/kg of patient body weight per day to about 30 mg/kg of patient body weight per day. For parenteral administration the antihypertensively effective amount of compound is from about O.Ol mg/kg of patient body weight per day up to about 50- mg/kg of patient body weight per day and preferably from about 0.1 mg/kg of patient body weight per day up to about 20.0 mg/kg of patient body weight per day. For oral or parenteral administration the cardiotonically effective amount of compound is from about 0.1 mg/kg of patient body weight per day up to about 50 mg/kg of patient body weight per day and preferably from about 0.1 mg/kg of patient body weight per day up to about 20.0 mg/kg of patient body weight per day. For oral or parenteral administration the anticoagulant effective amount of compound is from about 0.1 mg/kg of patient body weight per day up to about 100 mg/kg of patient body weight per day and preferably from about 0.1 mg/kg of patient body weight per day up to about 50 mg/kg of patient body weight per day. For oral administration a unit dosage may contain, for example, from 10 to 100 mg of the active ingredient. For parenteral administration a unit dosage may contain, for example, from 5 to 50 mg of the active ingredient. Repetitive daily administration of the compounds may be desired and will vary with the condition of the patient and the mode of administration. As used herein the term patient is taken to mean a warm blooded animal, for example, birds, such as chickens and turkeys, and mammals, such as primates, humans, sheep, horses, bovine cows and bulls, pigs, dogs, cats, rats and mice. For oral administration the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, powders, solutions, suspensions or emulsions. The solid unit dosage forms can be a capsule which can be of the ordinary gelatin type containing, for example, lubricants and inert filler, such as lactose, sucrose and cornstarch. In another embodiment, the compounds of the invention can be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with binders, such as acacia, cornstarch or gelatin, disintegrating agents such as potato starch or alginic acid, and a lubricant such as stearic acid or magnesium stearate. For parenteral administration the compounds may be administered as injectable dosages of a solution or suspension of the compound in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid such as water and oils with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Illustrative of oils which can be employed in these preparations are those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil and mineral oil. in general, water, saline, aqueous dextrose and related sugar solutions, ethanol and glycols such as propylene glycol or polyethylene glycol can be used as liquid carriers for injectable solutions. Particularly preferred are combinations of the above carriers such as aqueous ethanol or propylene glycol-aqueous ethanol at alkaline pH. The compounds can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber manufactured by the Dow Corning Corporation. Following are illustrative pharmaceutical formulations which may be employed in practicing the present invention: Preparation of a Tablet Formulation Per Tablet a) 1,3-Dihydro-4-(methoxybenzoyl)-5- 100 mg (methoxymethyl)-2H-imidazol-2-one b) Cornstarch 15 mg c) Lactose 33.5 mg d) Magnesium stearate 1.5 mg Preparation of a Parenteral Formulation a) 1,3-Dihydro-4-(4-methoxybenzoyl)-5- 0.100 g (methoxymethyl)-2H-imidazol-2-one b3 Sodium hydroxide 0.025 g c) Ethanol 1.516 g d) Propylene glycol 8.264 g e) Water for injection qs ad 20.0 ml The following examples are set forth to illustrate the preparation of compounds employed in the present invention but should not be construed as limiting it in any way. EXAMPLE 1 To a stirred mixture of 98.1 g (1 mole of 1,3-di- hydro-4-methyl-2H-imidazol-2-one, 266.7 g (2 moles) of anhydrous aluminum chloride and 500 ml of nitrobenzene there is added dropwise over 10 minutes, 158.6 g (1 mole) of ±-fluorobenzoyl chloride. The mixture is stirred at 60-650C for 6 hours, then poured onto 2 kg of ice. The precipitate which forms is separated by filtration, washed with diethyl ether and water and recrystallized from dimethylformamide to give l,3-dihydro-4-(4-fluorobenzoyl)-5- methvl-2H-imidazol-2-one melting at about 289-2920C. If the above procedure is repeated using 1,3-dihydro4-methyl-2H-imidazol-2-one and the appropriate acid chloride, the following compounds are obtained: 1,3-Dihydro-4-methyl-5-[4-(methylsulfonyl)benzoyl]-2H- imidazol-2-one. 1, 3-Dihydro-4- (4-methoxybenzoyl) -5-methyl-2H-imi- dazol-2-one melting at about 257258oC (dec.) after recrystallization from isopropanol-water. 4-Benzoyl-1, 3-dihydro-5-methylimidazol-2-one melting at about 250-2540C. l,3-Dihydro-4-methyl-5- (2-thiophenecarbonyl) -2H- imidazol-2-one melting at about 212-2150C. In this case, the material obtained after pouring the mixture onto ice water is extracted into ethyl acetate and the ethyl acetate solution is dried and the solvent is evaporated. 1, 3-Dihydro-4- (3, 4-dimethoxybenzoyl) -5-methyl-2H- imidazol-2-one melting at about 257-2590C after recrystallization twice from ethanol-water. 1, 3-Dihydro-4- (2-furoyl) -5-methyl-2H-imidazol-2-one melting at about 214-2160C after recrystallization twice from methanol. 1,3-Dihydro-4-(3,4-methylenedioxybenzoyl)-5-methyl2H-imidazol-2-one melting at about 293-2960C (dec). 1,3-Dihydro-5-ethyl-4-(4-methoxybenzoyl)-2H-imida- zol-2-one melting at about 1320C (dec). 1, 3-Dihydro-5-methyl-4- (4-pyridinecarbonyl) -2H-imida- zol-2-one melting at about 296 C (dec). 4-Acetyl-1,3-dihydro-5-methylimidazol-2-one melting at about 314-3160C. EXAMPLE 2 The sodium salt of 1,3-dihydro-4-(4-methoxybenzoyl)5-methyl-2H-imidazol-2-one is prepared from 7.0 g of 1, 3-dihydro-4- (4-methoxybenzoyl) -5-methyl-2H-imidazol-2-one in 100 ml of methanol with the addition of 1.6 g of sodium methoxide. A mixture is prepared from 8.0 g of this sodium salt, 120 ml of dimethylsulfoxide, 15.2 g of powdered sodium hydroxide, and 19.5 g of methyl iodide. This mixture is stirred at room temperature for 60 minutes and then poured into 800 ml of water. The resulting mixture is then extracted with methylene chloride and the solvent is evaporated from the extract to give a solid. This is crystallized from ether to give 1,3-dihydro-4-(4-methoxy benzoyl) -1,3,5-trimethyl-2H-imidazol-2-one melting at about 109-111 C. EXAMPLE 3 To 2.0 g of 1,3-dihydro-4-(4-methoxybenzoyl)-5-methyl-2H-imidazol-2-one in 30 ml of dimethyl sulfoxide is added 0.29 g of sodium hydride and 1.22 g of methyl iodide. The mixture is stirred at 220C for 30 minutes, poured in methylene chloride, and washed with water. The methylene chloride solution is dried and the solvent is evaporated to leave an oil which is triturated with chloroform to give a solid. This solid is recrystallized from methanol to give 1,3-dihydro-(l or 3),5-dimethyl-4-(4methoxybenzoyl3-2H-imidazol-2-one melting at about 2252280C. EXAMPLE 4 A mixture of 46.4 g of 1,3-dihydro-4-(4-methoxybenzoyl)-5-methyl-2H-imidazol-2-one and 200 ml of acetic anhydride is refluxed for 2 hours. The mixture is distilled to remove 100 ml of acetic anhydride and acetic acid; this is replaced by fresh acetic anhydride and refluxing is resumed. After a total of 4 hours of reflux, excess acetic anhydride is evaporated under reduced pressure and the resulting residue is crystallized from ethanol to give 1,3-diacetyl-1,3-dihydro-4-(4-methoxybenzoyl)-5-methyl-2Himidazol-2-one melting at about 123-1250C. If the above procedure is repeated using acetic anhydride and the appropriate substituted 1,3-dihydro-2Himidazol-2-one, the following compounds are obtained: 4-Benzoyl-1,3-diacetyl-1,3-dihydro-5-methyl-2H-imidazol-2-one melting at about 120-1220C, 1, 3-Diacetyl-1, 3-dihydro-4- (4-fluorobenzoyl) -5- methyl-2H-imidazol-2-one melting at about 102-1030C. 1,3-Diacetyl-1,3-dihydro-4-(4-dimethylaminobenzOyl)- 5-methyl-2H-imidazol-2-one melting at about 183-1840C, 1, 3-Dihydro-l,3,4-triacetyl-5-methyl-2H-imidazol-2-one melting at about 73-750C. 1,3-Diacetyl-1,3-dihydro-4-t3,4-dimethoxybenzOyl)- 5-methyl-2H-imidazol-2-one. 1,3-Diacetyl-1,3-dihydro-4-(3,4-methylenedioxybenzoyl)-5-methyl-2H-imidazol-2-one. 1,3-Diacetyl-1,3-dihydro-4-(4-methylsulfonylbenzOyl)- 5-methyl-2H-imidazol-2-one. l,3-Diacetyl-1,3-dihydro-4-(2-furoyl)-5-methyl-2H- imidazol-2-one. 1,3-Diacetyl-1,3-dihydro-4-(2-thiophenecarbonyl)- 5-methyl-2H-imidazol-2-one. 1,3-Diacetyl-1,3-dihydro-5-methyl-4-(4-pyridinecarbonyl)-2H-imidazol-2-one. 1,3-Diacetyl-1,3-dihydro-5-ethyl-4-(4-methoxybenzOyl)- 2H-imidazol-2-one. EXAMPLE 5 A mixture of 55.5 g (0.176 mole) of 1,3-diacetyl-1,3 dihydro-4- (4-methoxybenzoyl) -5-methyl-211-imidazol-2-one, 37.4 g (0.210 mole) of N-bromosuccinimide and about 100 mg of benzoyl peroxide in 500 ml of carbon tetrachloride is stirred at reflux temperature for 4 hours. The mixture is then cooled and filtered to remove the succinimide which formed. The solvent is evaporated from the filtrate and the resulting residue is crystallized from a mixture of 300 ml of ethyl acetate and 300 ml of hexane to give 5 (bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(4-methOxyben- zoyl)-2H-imidazol-2-one melting at about 135-1360C. If the above procedure is repeated using N-bromosuccinimide and the appropriate substituted 1,3-diacetyl1,3-dihydro-2H-imidazol-2-one, the following compounds are obtained: 5-(Bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(4-fluorobenzoyl)-2H-imidazol-2-one melting at about 113-1200C. 5-(Bromomethyl)-1,3-dihydro-1,3,4-triacetyl-2H-imida- zol-2-one melting at about 88-900C. 4-Benzoyl-5-(bromomethyl) -l,3-diacetyl-l,3-dihydro-2H- imidazol-2-one. 5-(Bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(3,4-dimethoxybenzoyl)-2H-imidazol-2-one. 5-(Bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(3,4-methyl enedioxybenzoyl) -2H-imidazol-2-one. 5-(Bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(4-methylsulfonylbenzoyl)-2H-imidazol-2-one. 5-(Bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(4-dimethyl aminobenzoyl) -2H-imidazol-2-one. 5-(Bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(2-furoyl3- 2H-imidazol-2-one. 5-(Bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(2-thiophene- carbonyl) -2H-imidazol-2-one. 5-(Bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(4-pyridine- carbonyl) -2H-imidazol-2-one. 5-(1-BromOethyl)-1,3-diacetyl-1,3-dihydro-4-(4-methoxy- benzoyl) -2H-imidazol-2-one. 5-(Bromomethyl)-1,3-dihydro-1,3-dimethyl-4-(4-methOxy- benzoyl) -2H-imidazol-2-one. 5-(Bromomethyl)-1,3-dihydro-4-(4-methoxybenzoyl)-(1 or 3) -methyl-2H-imidazol-2-one. EXAMPLE 6 A mixture of 50 g of 5-(bromomethyl)-1,3-diacetyl1,3 dihydro-4-(4-methoxybenzoyl)-2H-imidazol-2-one in 75 ml of 30% hydrobromic acid in acetic acid and 150 ml of acetic acid is heated to 800C on a steam bath and allowed to stand for 2 hours. The mixture is then evaporated to dryness under reduced pressure and the residue is crystallized from acetic acid and then dried in vacuo at 800C over potassium hydroxide. This gives 5-(bromomethyl)-1,3 dihydro-4- (4-methoxybenzoyl) -2H-imidazol-2-one melting at about 205-2070C with decomposition. If the above procedure is repeated using the appropriate 5-(bromomethyl)-l,3-diacetyl-l,3-dihydro-2H-imida- zol-2-one, the following products are obtained: 5-(Bromomethyl3-1,3-dihydro-4-(4-Eluorobenzoyl3-2B- imidazol-2-one melting at greater than 300oC with decomposition. 4-Benzoyl-5- (bromomethyl) -l,3-dihydro-2H-imidazol-2- one. 5-(Bromomethyl)-1,3-dihydro-4-(3,4-dimethoxybenzOyl)- 2H-imidazol-2-one. 5-(Bromomethyl)-1,3-dihydro-4-(3,4-methylenedioxyben zoyl) -2H-imidazol-2-one. 5- (Bromomethyl) -1,3-dihydro-4- (4-methylsulfonylbenzoyl) - 2H-imidazol-2-one. 5-(Bromomethyl)-1,3-dihydro-4-(4-dimethylaminobenzOyl)- 2H-imidazol-2-one. 5-(Bromomethyl)-1,3-dihydro-4-(2-furoyl)-2H-imidazol2-one. 5-(Bromomethyl)-1,3-dihydro-4-(2-thiophenecarbonyl)2H-imidazol-2-one. 4-Acetyl-5- (bromomethyl) -1, 3-dihydro-2H-imidazol-2- one. 5-(Bromomethyl)-1,3-dihydro-4-(4-pyridinecarbonyl)-2Himidazol-2-one. 5-(1-Bromoethyl)-1,3-dihydro-4-(4-methoxybenzOyl)-2H- imidazol-2-one. EXAMPLE 7 A solution of 4.0 g of 5-(bromomethyl)-1,3-diacetyl 1, 3-dihydro-4- (4-methoxybenzoyl) -2H-imidazol-2-one in 50 ml of dry tetrahydrofuran is cooled to -780C under argon, 1.0 ml of dry methanol is added by syringe, and the solution is allowed to warm to 250C over 1.5 hours. Concentrated hydrobromic acid (1 ml) is then added and the mixture is stirred at 250C overnight. The solvent is then evaporated and the residual solid is recrystallized twice from a mixture of methanol and water to give 1,3-dihydro 4- (4-methoxybenzoyl) -5- (methoxymethyl) -2H-imidazol-2-one melting at about 211-2120C with decomposition. This compound has the following structural formula: EMI13.1 EXAMPLE 8 If the procedure of Example 7 is repeated using 5 (bromomethyl)-1,3-diacetyl-1,3-dihydro-4-(4-methOxybenzOyl)- 2H-imidazol-2-one and the appropriate alcohol, the following compounds are obtained: 1, 3-Dihydro-4- (4-methoxybenzoyl) -5- (isopropoxymethyl) - 2H-imidazol-2-one. 1,3-Dihydro-4-(4-methoxybenzoyl)-5-[(1-pentyloxy3- methyl3-2H-imidazol-2-one. 5-(Benzyloxymethyl3-1,3-dihydro-4-(4-methoxybenzOyl3- 2H-imidazol-2-one. EXAMPLE 9 If the appropriate 4-substituted 5-(bromoalkyl)- l,3-diacetyl-l,3-dihydro-2H-imidazol-2-one is reacted with methanol according to the procedure described in Example 7, the following compounds are obtained: 1,3-Dihydro-4-(4-fluorobenzoyl)-5-(methoxymethyl)- 2H-imidazol-2-one. 4-BenzOyl-1,3-dihydro-5-(methoxymethyl)-2H-imidazol- 2-one. 1,3-Dihydro-4-(3,4-dimethoxybenzoyl)-5-(methoxymethyl)2H-imidazol-2-one. 1,3-Dihydro-5-(methoxymethyl)-4-(3,4-methylenedioxy- benzoyl)-2H-imidazol-2-one. 1,3-Dihydro-5-(methoxymethyl)-4-(4-methylsulfonyl- benzoyl) -2H-imidazol-2-one. 1,3-Dihydro-4-(4-dimethylaminobenzoyl)-5-(methoxy- methyl)-2H-imidazol-2-one. 1, 3-Dihydro-4- (4-methoxybenzoyl) -5- (methoxymethyl) - 1,3-dimethyl-2H-imidazol-2-one. 1,3-Dihydro-4-(2-furoyl)-5-(methoxymethyl3-2H-imidazol- 2-one. 1,3-Dihydro-5-(methoxymethyl)-4-(2-thiophenecar- bonyl)-2H-imidazol-2-one. l,3-Dihydro-5- (methoxymethyl) -4- (4-pyridinecarbonyl) - 2H-imidazol-2-one. 1,3-Dihydro-5-(1-methoxyethyl)-4-(4-pyridinec rbonyl)- 2H-imidazol-2-one. 4-Acetyl-1,3-dihydro-5-(methoxymethyl3-2H-imidazol-2- one. EXAMPLE 10 A solution of 3.0 g of 5-(benzyloxymethyl)-l,3-dihy- dro-4-(4-methoxybenzoylF2H-imidazol-2-one in 400 ml of ethanol containing 0.5 ml of concentrated hydrochloric acid is hydrogenated over 2.0 g of 10% palladium-on-charcoal catalyst in a Parr shaker until 1 equivalent of hydrogen is consumed. The catalyst is then removed by filtration and the solvent is evaporated to leave a residue which is crystallized from 50% aqueous ethanol to give l,3-dihydro-5- (hydroxymethyl) -4- (4-methoxybenzoyl) -2H- imidazol-2-one. EXAMPLE 11 5-(Bromomethyl)-1,3-dihydro-4-(-4-methoxybenzOyl)-2H- imidazol-2-one (3.1 g) is dissolved in 80 ml of acetic acid by warming on a steam bath. The solution obtained is allowed to cool to about 25-450C and 1.7 g of silver acetate is added. The mixture is stirred at 250C for 16 hours and the precipitate which forms (silver bromide) is removed by filtration. The filtrate is concentrated to about 10 ml and a solid crystallizes. This is separated by filtration and recrystallized from acetic acid to give 5-[(acetylOxy)methyl]-1,3-dihydro-4-(4-methoxybenzOyl)-2H- imidazol-2-one melting at about 155-1620C. This compound has the following structural formula: EMI15.1 EXAMPLE 12 If the procedure of Example 11 is repeated using silver acetate and the appropriately substituted 5-(bromomethyl)-1,3-dihydro-2H-imidazol-2-one, the following compounds are obtained: 4-Acetyl-5-[ (acetyloxy)methyl]-1,3-dihydro-2H-imidazol 2-one. 5-[(Acetyloxy)methyl]-1,3-dihydro-4-(2-thiophene- carbonyl) -2H-imidazol-2-one. If the procedure of Example 11 is repeated using 5- (bromomethyl) -1, 3-dihydro-4- (4-methoxybenzoyl) -2H-imida- zol-2-one, propionic acid and silver propionate, the product obtained is l,3-dihydro-4- (4-methoxybenzoyl) -5- [(pro- pionyloxy) methyl] -2H-imidazol-2-one. Similarly, if 5-(bromomethyl)-1,3-dihydro-1,3-di- methyl-4- (4-methoxybenzoyl) -2H-imidazol-2-one is reacted with silver acetate, the product obtained is S-[(acetyl- oxy)methyl]-1,3-dihydro-1,3-dimethyl-4-(4-methoxybenzoyl)-2H-imidazol-2-one. EXAMPLE 13 To a solution of 6.8 g of silver nitrate in 40 ml of dry acetonitrile at OOC is added, dropwise, over a period of 15 minutes, a solution of 1,3,4-triacetyl-5-(bromomethyl)-1,3-dihydro-2H-imidazol-2-one (in acetonitrile). The mixture is stirred at OOC for 45 minutes and the precipitate which forms (silver bromide) is removed by filtration. The solvent is evaporated from the filtrate under reduced pressure and the residue is partitioned between ethyl acetate and water. The ethyl acetate phase is separated, washed with water and dried over magnesium sulfate and the solvent is then evaporated. The residue is then recrystallized from a mixture of ethyl acetate and hexane and then from ethyl acetate alone to give (1,3,4 triacetyl-1,3-dihydro-2-oxo-2H-imidazol-5-yl)methyl nitrate melting at about 135-1360C with decomposition. If the above procedure is repeated using silver nitrate and 5-(bromomethyl)-1,3-diacetyl-1,3-dihydro-4- (4-methoxybenzoyl) -2H-imidazol-2-one, the product obtained is [1,3-diacetyl-4-(4-methoxybenzoyl)-1,3-dihydro-2-oXo- 2H-imidazol-5-yl]methyl nitrate melting at about 104104.50C. This compound has the following structural formula: EMI17.1 EXAMPLE 14 To a cold solution (100C) of 1.9 g of [1,3-diacetyl 4-(4-methOxybenzOyl)-1,3-dihydro-2-oxo-2H-imidazol-5-yllmethyl nitrate in 30 ml of ethyl ether and 20 ml of ethyl acetate there is added a solution of 470 mg of piperidine in 10 ml of ethyl ether and the solution is stirred at 250C for 30 minutes. Water (30 ml) is added and the precipitate which forms is separated and recrystallized twice from ethyl acetate to give [l-acetyl-1,3-dihydro-5-(4-methoxyben- zoyl)-2-oxo-2H-imidazol-4-yl]methyl nitrate melting at about 16S-1660C with decomposition.

Claims: WHAT IS CLAIMED IS: 1. A compound of the formula: EMI18.1 wherein each R independently is hydrogen,lser alkyl of l-4C, lower a Z noyl of 2-4C,or benzoyl; d is lower alkyl of 1-4C, phenyl halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3, 4-meth- ylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl; R2 is hydrogen or lower alkyl of 1-4C; and R3 is hydrogen, lower alkyl of 1-4C, lower alkanoyl of 2-4C or nitro. 2. A compound according to Claim 1 which has the formula: EMI18.2 wherein R is hydrogen, lower alkyl of 1-4C, lower alkanoyl of 2-4C, or benzoyl; R1 is lower alkyl of 1-4C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3, 4-meth- ylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl; R2 is hydrogen or lower alkyl of 1-4C; and R3 is hydrogen, lower alkyl of 1-4C, or lower alkanoyl of 2-4C. 3. A compound according to Claim 1 which has the formula: EMI19.1 wherein R is hydrogen, lower alkyl of l-4C, lower alkanoyl of 2-4C, or benzoyl; R1 is lower alkyl of 1-4C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methylsulfonyl- phenyl, dimethylaminophenyl, dimethoxyphenyl, 3,4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl. 4. A compound according to Claim 1 which has the formula: EMI19.2 wherein R1 is lower alkyl of 1-4C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3,4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl. 5. A compound according to Claim 1 which is 1,3-di hydro-4-(4-methoxybenzoyl)-5-(methoxymethyl3-2H-imidazol- 2-one. 6. A compound according to Claim 1 which is 4-[(ace tylOxy)methyl]-1,3-dihydro-5-(4-methoxybenzoyl)-2H-imida- zol-2-one. 7. A compound according to Claim 1 which has the formula: EMI19.3 wherein R is lower alkyl of 1-4C, lower alkanoyl of 2-4C, or benzoyl; R1 is lower alkyl of 1-4C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3,4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl. 8. A compound according to Claim 1 which is [1,3 diacetyl-4- (4-methoxybenzoyl) -1,3-dihydro-2-oxo-2H-imida- zol-5-yl]methyl nitrate. 9. A process for preparing a compound of the formula: EMI20.1 wherein each R independently is hydrogen,lower alkyl of i-4C,lower alkanoyl ofH2-4C,or benzoyl; R1 is lower alkyl of 1-4C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3, 4-meth- ylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl; R2 is hydrogen or lower alkyl of 1-4C; and R3 is hydrogen, lower alkyl of 1-4C, lower alkanoyl of 2-4C or nitro; which comprises reacting a compound of the formula: EMI20.2 wherein R, R1 and R2 are defined as above, with a compound selected from HOR4 and AgOR5 wherein R4 is lower alkyl of 1-4C or benzyl and R5 is lower alkanoyl of 2-4C or nitro to give the corresponding oxymethyl compound followed by, when R4 is benzyl, catalytic hydrogenolysis to give the compound wherein R3 is hydrogen. 10. A compound of claim 1 for use in treating hypertension, cardiac failure or blood clotting. 11. A pharmaceutical preparation for oral or parenteral administration containing a compound of claim 1 as the active ingredient CLAIMS FOR AUSTRIA 1. A process for preparing a compound of the formula EMI22.1 wherein each R independently is hydrogen, lower alkyl of 1-4C, lower alkanoyl of 2-4C, or benzoyl; R1 is lower alkyl of 1-4C, phenyi,halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3, 4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl; R2 is hydrogen or lower alkyl or 1-4C; and R3 is hydrogen, lower alkyl of 1-4C, lower alkanoyl of 2-4C or nitro; which comprises reacting a compound of formula EMI22.2 wherein R, R1 and R2 are defined as above, with a compound selected from HOR4 and AgOR5 wherein R4 is lower alkyl of 1-4C or benzyl and R5 is lower alkanoyl of 2-4C or nitro to give the corresponding oxymethyl compound followed by, when R4 is benzyl, catalytic hydrogenolysis to give the compound wherein R3 is hydrogen; said process being further characterized in that a) when a compound of formula EMI23.1 is obtained wherein R1, R2, and R3 are as defined above and one or both R represent a lower alkanoyl of 2-4C or benzoyl group, it may be transformed into the corresponding compound wherein one or both R are hydrogen by removal of the acyl group or groups by treatment with acid when R3 is lower alkyl of 1-4C or lower alkanoyl of 2-4C and with an amine when R3 is nitro; and b) when a compound of formula EMI23.2 is obtained wherein R is hydrogen, and R1, R2 and R3 are as defined above, it may be converted to the corresponding compound of the above formula wherein R stands for a lower alkanoyl of 2-4C or benzoyl group by reaction with the appropriate acid anhydride or acid chloride. 2. A process according to claim 1 for preparing a compound of the formula EMI24.1 wherein R is hydrogen, lower alkyl of 1-4C, lower alkanoyl of 2-4C, or benzoyl; R1 is lower alkyl of 1-4C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3-4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl; R2 is hydrogen or lower alkyl of 1-4C; and R3 is hydrogen, lower alkyl of 1-4C or lower alkanoyl of 2-4C. 3. A process according to claim 1 for preparing a compound-of the formula: EMI24.2 wherein R is hydrogen, lower alkyl of 1-4C, lower alkanoyl of 2-4C or benzoyl; R1 is lower alkyl of 1-4C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3, 4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl. 4. A process according to claim 1 for preparing a compound of the formula: EMI25.1 wherein R1 is lower alkyl of 1-4C, phenyl, halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3,4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl. 5. A process according to claim 1 for preparing a compound of the formula EMI25.2 wherein R is lower alkyl of 1-4C, lower alkanoyl of 2-4C, or benzoyl; R1 is lower alkyl of 1-4C, phenyl halophenyl, methylphenyl, methoxyphenyl, methylsulfonylphenyl, dimethylaminophenyl, dimethoxyphenyl, 3,4-methylenedioxyphenyl, 2-furyl, 2-thienyl or pyridyl. 6. A process according to claim 1 for preparing 5-/(acetyloxy)methyl7-1,3-dihydro-4-(4-methoxybenzoyl)-2H-imidazol-2-one. 7. A process according to claim 1 for preparing 1,3-dihydro-4-t4-methoxybenzoyl)-5-tmethoxymethyl)-2H-im- idazol-2-one. 8. A process according to claim 1 for preparing / 1,3-diacetyl-4-t4-methoxybenzoyl)-1,3-dihy- dro-2-oxo-2H-imidazol-5-yl7methyl nitrate.

Inventors: DAGE, RICHARD C., GRISAR, J. MARTIN, SCHNETTLER, RICHARD A.
Applicants: MERRELL DOW PHARMACEUTICALS INC.
Application year: 1982
Main classification: C07D233
IPC codes: C07D409, A61K31, A61P9, C07D405, C07D401, A61P7, C07D233